CEM/C1 Cells

The CEM/C1 cell line is a derivative of the CCRF-CEM human T-cell leukemia cell line, specifically selected for its resistance to certain chemotherapeutic agents, notably the topoisomerase II inhibitor, doxorubicin. This selection confers the cell line with significant applications in the study of multidrug resistance, a prevalent challenge in the treatment of various cancers. The CEM/C1 line exhibits overexpression of the MDR1 gene, which encodes the P-glycoprotein, a key efflux transporter involved in the resistance of cells to chemotherapeutic drugs. Genetically, CEM/C1 cells are characterized by their human T-lymphoblastoid lineage, making them highly relevant for research into T-cell biology and leukemia. The cells maintain a robust proliferative capacity and can be used in in vitro experiments aimed at understanding the cellular mechanisms of drug resistance, apoptosis, and the efficacy of new chemotherapeutic agents. These cells also provide a valuable tool for pharmacological studies, particularly in evaluating the pharmacodynamics and pharmacokinetics of anticancer drugs within a controlled experimental setting. Due to their drug-resistant properties, CEM/C1 cells are particularly useful in the development of treatment strategies that circumvent or directly target mechanisms of drug resistance. Studies utilizing this cell line can contribute to the broader understanding of cancer cell survival tactics and potentially lead to the development of more effective cancer therapies, especially for refractory or relapsed T-cell leukemia. Leukemia cell lines, Peripheral blood, T-cell acute lymphoblastic leukemia, Growth Conditions: Suspension, Biosafety level: BSL 1